<div><div></div><div>Humacyte entered into an Underwriting Agreement to sell 47,619,048 shares of common stock at $1.05 per share. Barclays Capital, BTIG, and Titan Partners Group, as representatives of the underwriters, also received a 30-day option to purchase up to 7,142,857 additional shares at the same price. Net proceeds are expected to be approximately $46.8 million, or about $53.85 million if the option is fully exercised. The offering is expected to close on or about June 12, 2026, subject to customary conditions.Agreement details:<ul><li>Agreement type: Underwriting agreement for common stock offering</li><li>Counterparty: Barclays Capital; BTIG; Titan Partners Group, as representatives of the underwriters</li><li>Signed / Effective: Jun 10 2026 / same</li><li>Duration / Termination: At will</li><li>Reason: Raise capital through public equity offering</li></ul>Original SEC Filing: Humacyte, Inc. [ HUMA ] - 8-K - Jun. 11, 2026<section>Disclaimer<div>This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.</div></section></div></div>

HUMA

Humacyte entered an underwriting agreement to sell 47.6 million shares at $1.05 each, raising approximately $46.8 million in net proceeds. Underwriters have a 30-day option to purchase up to 7.1 million additional shares. The offering is expected to close around June 12, 2026.

Humacyte Enters Underwriting Agreement for 47.6M-Share Offering at $1.05, Nets ~$46.8M